Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KPC Pharmaceuticals's Other Current Payables for the quarter that ended in Mar. 2026 was ¥1,482 Mil.
KPC Pharmaceuticals's quarterly Other Current Payables
declined
from Sep. 2025 (¥2,226 Mil) to Dec. 2025 (¥1,642 Mil) and
declined
from Dec. 2025 (¥1,642 Mil) to Mar. 2026 (¥1,482 Mil).
KPC Pharmaceuticals's annual Other Current Payables
increased
from Dec. 2023 (¥1,759 Mil) to Dec. 2024 (¥3,198 Mil) but then
declined
from Dec. 2024 (¥3,198 Mil) to Dec. 2025 (¥1,642 Mil).
KPC Pharmaceuticals Other Current Payables Related Terms
KPC Pharmaceuticals Other Current Payables Historical Data
* Premium members only.
The historical data trend for KPC Pharmaceuticals's Other Current Payables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPC Pharmaceuticals Other Current Payables Calculation
Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.
What does a Other Current Payables of ¥1,482 Mil mean?
KPC Pharmaceuticals (SHSE:600422) has a Other Current Payables of ¥1,482 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on KPC Pharmaceuticals and its competitors.
Is KPC Pharmaceuticals' Other Current Payables too high?
KPC Pharmaceuticals' current Other Current Payables is ¥1,482 Mil. Overall, KPC Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' Other Current Payables compare to ZTS?
KPC Pharmaceuticals' Other Current Payables of ¥1,482 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on KPC Pharmaceuticals and its competitors. KPC Pharmaceuticals's current Other Current Payables is ¥1,482 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.04, compared to a current price of ¥9.10 — trading 24.4% below its estimated fair value. The current Other Current Payables is ¥1,482 Mil. KPC Pharmaceuticals' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current Other Current Payables is ¥1,482 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?
Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥9.10 is trading 24.4% below its estimated GF Value™ of ¥12.04.
GuruFocus considers KPC Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SHSE:600422:
Other Current Payables: ¥1,482 Mil
GF Value™: ¥12.04 vs. price of ¥9.10 (24.4% below fair value)
No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
66GF Score
Get the complete analysis for SHSE:600422
Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600422 has been successfully added to your 
